Eton Pharmaceuticals/$ETON
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Eton Pharmaceuticals
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.
- Ticker
- $ETON
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 44
- Headquarters
- Deer Park, United States
- Website
- www.etonpharma.com
ETON Metrics
BasicAdvanced
$1.5B
121.91
$0.43
0.87
-
Price and volume
Market cap
$1.5B
Beta
0.87
52-week high
$66.37
52-week low
$14.27
Average daily volume
534K
Financial strength
Current ratio
1.52
Quick ratio
1.146
Long term debt to equity
0.433
Total debt to equity
0.627
Interest coverage (TTM)
4.52%
Profitability
EBITDA (TTM)
25.178
Gross margin (TTM)
61.41%
Net profit margin (TTM)
12.02%
Operating margin (TTM)
19.54%
Effective tax rate (TTM)
0.49%
Revenue per employee (TTM)
$2,400,000
Management effectiveness
Return on assets (TTM)
11.86%
Return on equity (TTM)
35.97%
Valuation
Price to earnings (TTM)
121.912
Price to revenue (TTM)
13.434
Price to book
31.69
Price to tangible book (TTM)
1,627.57
Price to free cash flow (TTM)
-5,293.163
Free cash flow yield (TTM)
-0.02%
Free cash flow per share (TTM)
-0.01
Growth
Revenue change (TTM)
81.49%
Earnings per share change (TTM)
-374.29%
3-year revenue growth (CAGR)
53.81%
3-year earnings per share growth (CAGR)
259.83%
What the Analysts think about ETON
Analyst ratings (Buy, Hold, Sell) for Eton Pharmaceuticals stock.
Analyst projections of the future price of Eton Pharmaceuticals stock.
Bulls say / Bears say
Second-quarter revenue nearly doubled year on year to $37.6 million, and Eton raised its 2026 revenue target to more than $145 million while lifting its adjusted EBITDA margin target to at least 35%. That points to strong near-term sales momentum and improving operating leverage. (Eton Pharmaceuticals)
Growth is showing across several products, not just one: Eton reported strong year-on-year sales growth in INCRELEX, ALKINDI SPRINKLE, GALZIN and Carglumic Acid, while its adrenal franchise passed 600 active patients. DESMODA was also seeing early patient uptake after its March launch. (Eton Pharmaceuticals)
Eton has several potential growth catalysts beyond its current sales base. AMGLIDIA received FDA Fast Track designation, with an NDA targeted by year-end 2026, while a KHINDIVI label expansion and the ET-700 study could create further opportunities if they succeed. (Eton Pharmaceuticals)
Sales and receivables are heavily concentrated in one specialty pharmacy: AnovoRx accounted for 90.4% of first-half product sales and 88.1% of receivables at the end of June. Any disruption to that relationship or its fulfilment and collections could affect a large share of the business. (StockTitan)
Adjusted gross margin fell to 73% from 75% a year earlier, partly because overseas INCRELEX sales carry a negative gross margin. If that sales mix grows, headline revenue growth may translate less well into gross profit. (Eton Pharmaceuticals)
At 30 June, Eton had $26.8 million in cash against about $27.9 million of debt under its credit facility, leaving little cash headroom before other needs. The filing also sets out principal repayments restarting in November 2026, adding to the demands on cash as development spending rises. (StockTitan, Merlin Trader)
Data summarised monthly by Lightyear AI. Last updated on 7 Oct 2026.
ETON Financial Performance
Revenues and expenses
ETON Earnings Performance
Company profitability
Upcoming events
No upcoming events
ETON News
AllArticlesVideos
Funds containing ETON
Fund name | Fund size | $ETON weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.10% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.10% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.04% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.04% |
Xtrackers MSCI World Small Cap$XSWC | $183M | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.